Literature DB >> 21053036

Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.

Stergios A Polyzos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21053036     DOI： 10.1007/s10067-010-1611-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  13 in total

Review 1.  The role of zoledronic acid in the management of osteoporosis.

Authors:  Michael Maricic
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

2.  Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.

Authors:  David Hosking; Kenneth Lyles; Jacques P Brown; William D Fraser; Paul Miller; Manuel Diaz Curiel; Jean-Pierre Devogelaer; Michael Hooper; Guoqin Su; Ken Zelenakas; Judy Pak; Taiwo Fashola; Youssef Saidi; Erik Fink Eriksen; Ian R Reid
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

3.  Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.

Authors:  Andrew Grey; Mark Bolland; Diana Wattie; Anne Horne; Greg Gamble; Ian R Reid
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

4.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

5.  The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.

Authors:  Andrew Grey; Mark J Bolland; Diana Wattie; Anne Horne; Greg Gamble; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2008-12-02       Impact factor: 5.958

Review 6.  Pathogenesis and management of Paget's disease of bone.

Authors:  Stuart H Ralston; Anne L Langston; Ian R Reid
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

7.  Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.

Authors:  J-P Devogelaer; P Bergmann; J-J Body; Y Boutsen; S Goemaere; J-M Kaufman; J-Y Reginster; S Rozenberg; S Boonen
Journal:  Osteoporos Int       Date:  2008-05-27       Impact factor: 4.507

8.  Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.

Authors:  Avraam Avramidis; Stergios A Polyzos; Efstratios Moralidis; Georgios Arsos; Zoe Efstathiadou; Konstantinos Karakatsanis; Georgios Grollios; Marina Kita
Journal:  J Bone Miner Metab       Date:  2008-11-01       Impact factor: 2.626

9.  Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.

Authors:  Daniela Merlotti; Luigi Gennari; Giuseppe Martini; Fabrizio Valleggi; Vincenzo De Paola; Annalisa Avanzati; Ranuccio Nuti
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

10.  Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.

Authors:  Michael McClung; Paul Miller; Chris Recknor; Peter Mesenbrink; Christina Bucci-Rechtweg; Claude-Laurent Benhamou
Journal:  Obstet Gynecol       Date:  2009-11       Impact factor: 7.661
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.